Cellectisの機関の所有権
Cellectisの機関の所有権は何ですか。
Cellectisの機関の所有権は24.33%です。
機関の所有権の定義は何ですか。
機関所有権は、ミューチュアル・ファンドまたは年金基金、保険会社、投資会社、その他の資金を管理する他の団体が所有する会社の株式数です。
Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.
Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.
NASDAQのセクタHealth Careにおける機関の所有権の企業と比べるCellectis
Cellectisは何をしますか。
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Cellectisと類似の機関の所有権
- The Westaimの機関の所有権は24.27%です。
- The Westaimの機関の所有権は24.27%です。
- Sun Pharmaceutical Industriesの機関の所有権は24.28%です。
- Newcore Goldの機関の所有権は24.28%です。
- Shanghai Medicilonの機関の所有権は24.32%です。
- Caledonia Mining Plcの機関の所有権は24.32%です。
- Cellectisの機関の所有権は24.33%です。
- LAIX Incの機関の所有権は24.35%です。
- Defiance Silverの機関の所有権は24.35%です。
- Gogold Resourcesの機関の所有権は24.37%です。
- ARK ETF Trust - ARK Genomic Revolution ETFの機関の所有権は24.38%です。
- CIIG Merger Corpの機関の所有権は24.38%です。
- Zynerba Pharmaceuticals Incの機関の所有権は24.38%です。